EFPIA Challenges Conclusions Of New EC Report On Drug Pricing
This article was originally published in Scrip
Executive Summary
The European Commission may not have much of a say in drug pricing matters beyond making sure member states meet the requirements of the price transparency directive, but it certainly makes no bones about encouraging countries to act more collaboratively in dealing with the high prices of some new medicines and thereby improving access.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.